16TH Clinical Trials on Alzheimer's Disease (CTAD) | October 24-27, 2023
October 25, 2023 — Reda et al.
Fosgonimeton, a Small-Molecule Positive Modulator of the HGF/MET System, Attenuates Amyloid-β–Mediated Toxicity in Preclinical Models of Alzheimer’s Disease
